Cryptococcal meningitis: This World AIDS Day, it’s time to recognise an outsider

December 1, 2021

By Amir Shroufi, MSF South Africa Outsiders seldom get the attention they deserve. When it comes to conservation, for example, a few popular species attract most of the available funding – the rhino overshadows riverine rabbit. In the arts, jazz and...

Breakthrough in treatment of HIV-related cryptococcal meningitis gives Gilead another opportunity to fulfil its promise to scale up access to lifesaving drug

July 21, 2021

Today, as preliminary AMBITION trial results demonstrated a breakthrough in treatment of HIV-related cryptococcal meningitis, simplifying and shortening treatment by using a single dose of liposomal amphotericin B (L-AmB) in combination with existing oral therapy, Médecins Sans Frontières/Doctors Without Borders...

Gilead Sciences fails on promise to expand access to lifesaving drug for people living with HIV

June 27, 2019

Inaction by US pharmaceutical corporation Gilead to follow through on its so-called ‘access initiative’ leaves people unable to access a vital drug to treat a deadly infection. Delhi/Geneva - Pharmaceutical corporation Gilead Sciences has failed to deliver on promises to make...